Ozempic is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Remedyrepack Inc.. The primary component is Semaglutide.
| Product ID | 70518-2143_8b9ed314-8801-961d-e053-2a95a90a3962 |
| NDC | 70518-2143 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Ozempic |
| Generic Name | Semaglutide |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2019-06-11 |
| Marketing Category | NDA / NDA |
| Application Number | NDA209637 |
| Labeler Name | REMEDYREPACK INC. |
| Substance Name | SEMAGLUTIDE |
| Active Ingredient Strength | 1 mg/mL |
| Pharm Classes | GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2019-06-11 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA209637 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2019-06-11 |
| Ingredient | Strength |
|---|---|
| SEMAGLUTIDE | 1.34 mg/mL |
| SPL SET ID: | b5399d16-01c1-4315-af3c-7619fee86621 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0169-4130 | Ozempic | semaglutide |
| 0169-4132 | Ozempic | semaglutide |
| 0169-4136 | Ozempic | semaglutide |
| 0169-4181 | Ozempic | semaglutide |
| 0169-4772 | Ozempic | semaglutide |
| 50090-5138 | Ozempic | semaglutide |
| 50090-5139 | Ozempic | semaglutide |
| 70518-2143 | Ozempic | Ozempic |
| 0169-4501 | WEGOVY | semaglutide |
| 0169-4505 | WEGOVY | semaglutide |
| 0169-4517 | WEGOVY | semaglutide |
| 0169-4524 | WEGOVY | semaglutide |
| 0169-4525 | WEGOVY | semaglutide |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() OZEMPIC 79159431 4774881 Live/Registered |
Novo Nordisk A/S 2014-12-03 |